News for Pharmaxis Ltd (PXS.AX)

Published at

Sep 2, 2024 10:15 PM

by globenewswire.com

mixed

mixed

Liver Fibrosis Market Is Expected to Reach USD 43.98 Billion By 2030

The increase in emerging industries and the increasing investment in developing advanced technologies are opportunities for liver fibrosis market growth....

VX1.DE VRTX34.SA VRTX.MX VRTX SUNPHARMA-BL.NS PXSLY PXS.AX PFED.BA PFECL.SN PFE.SN PFE.MX PFE.DE PFE NVSN.MX NVSEF NVSD.BA NVS NOVN.SW N1VS34.SA MRKD.BA MRK.SN MRK.PA MRK.MX MRK GSK.L GSK GS7.DE GLAXF GIS.DE GILDD.BA GILD.MX GILD FGEN.MX FGEN DRNA BRM.DE BMYB34.SA BMY.MX BMY.BA BMY 6MK.DE 0QZU.L 0K9E.L 0IL8.L MYL JNJ DJNJ3.BA DJNJ2.BA

Read more →
Published at

Mar 8, 2024 7:37 AM

by gurufocus.com

positive

positive

Q4 2023 Pharmaxis Ltd Activities Report Call Transcript

Jul 31, 2023 / NTS GMTOperator Good afternoon, everyone. Our clock has now ticked pass midday. So we'll get started with today's quarterly investor briefing wit

PXSLY PXS.AX

Read more →
Published at

Mar 8, 2024 7:37 AM

by gurufocus.com

positive

positive

Pharmaxis Ltd Acquisdata Podcast with Gary Phillips on COVID-19 Impact and Response Transcript

Apr 29, 2020 / NTS GMTFiona Fox - Acquisdata Inc. - Media Well, Gary, it's been about six weeks, I think, since Australia locked down in response to the COVID-1

PXSLY PXS.AX

Read more →
Published at

Jul 24, 2023 4:35 PM

by globenewswire.com

mixed

mixed

Inhaled Antibiotics Market to Surpass US$ 2,213.2 Million by 2030, Says Coherent Market Insights

Inhaled antibiotics, when used for the long term, have demonstrated their effectiveness in reducing exacerbations and preserving lung function....

VENUSREM.NS VENUSREM.BO PXSLY PXS.AX CIPLA.NS CIPLA.BO LUPIN.NS LUPIN.BO INSM GILDD.BA BDXB BDX.MX BDX 0R19.L 0JAV.L PMI.SW PM.MX PM PHMO34.SA 4I1.DE

Read more →
Published at

Jul 12, 2023 5:52 AM

by themarketherald.com.au

negative

negative

Pharmaxis (ASX:PXS) releases “excellent” final set of interim data from phase two cancer trial

Pharmaxis (PXS) has released its final set of interim data for its phase two cancer trial, showing "excellent" results.

PXS.AX

Read more →
Published at

May 12, 2023 3:15 AM

by prnewswire.com

neutral

neutral

Global Cystic Fibrosis Treatment Market Report 2023: Sector is Expected to Reach $25.7 Billion by 2031 at a CAGR of 13.4%

/PRNewswire/ -- The

VX1.DE VRTX34.SA VRTX.MX VRTX PXSLY PXS.AX JNJ GIS.DE GILDD.BA GILD.MX GILD DJNJ3.BA DJNJ2.BA ABBV34.SA ABBV.MX ABBV.BA ABBV 4AB.DE 0QZU.L

Read more →
Published at

May 10, 2023 5:57 PM

by stockhead.com.au

mixed

mixed

Check Up Budget Edition: Which ASX healthcare stocks will reap benefits from the Budget?

Telehealth, mental health and aged care stocks rallied on Wednesday following the Budget announcement which include billions for healthcare.

REG.AX ONE.AX LME.AX JHC.AX GLH.AX 1ST.AX RGS.AX PXSLY PXS.AX PBP.AX OCC.AX MEB.AX MDBIF IVX.AX IPDQF IPD.AX IMM.AX HSC.AX CGS.AX ATX.AX ARUXF ADR.AX ACR.AX VTG.AX VLS.AX SOMNF SOM.AX SCU.AX RNO.AX RHT.AX PGC.AX PCK.AX EYE.AX CMP.AX CAN.AX CAJ.AX BXN.AX AMT.AX

Read more →
Published at

Apr 30, 2023 7:20 PM

by stockhead.com.au

mixed

mixed

Check Up: Healthcare is ripe for AI disruption, and Telix Pharma’s first $100m+ quarterly sales

The healthcare sector is ripe for disruption and artificial intelligence will play a big part in future drug discovery.

PSQ.AX PGC.AX OSX.AX OPT.AX OPT NOXOF NOX.AX IUGNF IMU.AX GSS.AX CYP.AX CKDXF BPH.AX ATX.AX 4DX.AX ZNO.AX SCU.AX RSH.AX PXSLY PXS.AX PAB.AX OCC.AX NC6.AX KZA.AX KMLXF IHL.AX IDT.AX FDMDF DVL.AX CMP.AX BITRF BIT.AX ARUXF AMT.AX ACR.AX 1AD.AX ZLD.AX VTG.AX VLS.AX UBI.AX TD1.AX SOMNF SOM.AX RNO.AX RHY.AX RHT.AX RGS.AX RAC.AX PYC.AX PNV.AX PCK.AX PBP.AX OVN.AX OSL.AX ONE.AX OIL.AX NYR.AX NXSCF NXS.AX MXC.AX MX1.AX MVF.AX MEM.AX MEB.AX MDR.AX MDC.AX MDBIF LBT.AX IVX.AX IPDQF IPD.AX IMRNW IMRN IMM.AX IMC.AX ICR.AX HCT.AX GTG.AX GLH.AX EYE.AX DXB.AX CSL.AX CPH.AX CGS.AX CAN.AX CALZF CAJ.AX BXN.AX BWXXF BWX.AX BNOEF BNO.AX AT1.AX ARX.AX AMDHF ALC.AX ADR.AX ADO.AX 1ST.AX

Read more →
Published at

Apr 26, 2023 6:40 PM

by stockhead.com.au

positive

positive

MoneyTalks: Brokers see blue sky for these 3 ASX biotech stocks, with massive price targets

Brokers Euroz Hartleys and Taylor Collison have put lofty target prices on 3 ASX biotechs - Pharmaxis, Botanix and Paragon Care.

PXS.AX PGC.AX EZL.AX

Read more →
Published at

Mar 14, 2023 1:30 PM

by globenewswire.com

mixed

mixed

Cystic Fibrosis Therapeutics Market Size is projected to reach USD 13.88 billion in 2030, growing at a CAGR of 9.12%: Straits Research

The global cystic fibrosis therapeutics market size was valued at USD 6.33 billion in 2021 and is expected to reach USD 13.88 billion in 2030 expanding at...

PXSLY PXS.AX GILDD.BA VTRSV VTRS.MX VTRS VIA.DE

Read more →
Published at

Mar 5, 2023 7:20 PM

by stockhead.com.au

mixed

mixed

Check Up: Almost half a billion US dollars raised to bring back mammoth, dodo, and Tassie tiger

Colossal Biosciences’ plans to bring the Tasmanian tiger and woolly mammoth back to life, but now it’s also betting on the iconic dodo.

TD1.AX RGS.AX RAC.AX FFC.AX EZL.AX PYC.AX PAB.AX OPT.AX OPT MX1.AX CMP.AX CKDXF AMT.AX VTG.AX VLS.AX SOMNF SOM.AX SCU.AX RNO.AX RHT.AX PXSLY PXS.AX PSQ.AX PNV.AX PGC.AX PBP.AX ONE.AX OCC.AX NYR.AX NC6.AX MVF.AX MEM.AX MEB.AX MDBIF LBT.AX IVX.AX IPDQF IPD.AX IMM.AX HCT.AX GTG.AX GSS.AX EYE.AX CGS.AX CAN.AX CALZF CAJ.AX BXN.AX BWXXF BWX.AX BNOEF BNO.AX ATX.AX ARUXF AMDHF ADR.AX ACR.AX

Read more →
Published at

Mar 3, 2023 6:52 AM

by stockhead.com.au

mixed

mixed

Closing Bell: ASX holds steady but microcaps slide into the weekend

A total of 10 out of 11 sectors were higher, led by Communication Services which rallied by 0.86%.

ZGL.AX VPR.AX VAL.AX TMX.AX SYA.AX SHO.AX MCT.AX GLH.AX DTR.AX CRS.AX TUA.AX RDN.AX OML.AX OLL.AX NCR.AX MDX.AX LCY.AX IHR.AX GLV.AX GBR.AX BTC.AX ABB.AX ZMM.AX QFY.AX PXSLY PXS.AX AJQ.AX

Read more →
Published at

Feb 1, 2023 5:46 PM

by stockhead.com.au

mixed

mixed

Check Up: The FDA refuses to give CBD a green light, but market doesn’t seem to care

The FDA declined regulate CBD-based supplements and food citing safety reasons, but the CBD index keeps going up.

PYC.AX PSQ.AX PGC.AX MSB.AX KZA.AX EYE.AX DVL.AX CAN.AX BXN.AX BNOEF BNO.AX ADO.AX SOMNF SOM.AX RSH.AX RHT.AX RGS.AX OSX.AX OSL.AX ONE.AX OIL.AX NXSCF NXS.AX MEB.AX MDC.AX MDBIF KMLXF IVX.AX IUGNF IMU.AX IDT.AX GLH.AX CYP.AX CMP.AX CAJ.AX AT1.AX ADR.AX 1ST.AX ZNO.AX ZLD.AX VTG.AX VLS.AX UBI.AX TD1.AX SCU.AX RNO.AX RHY.AX RAC.AX PXSLY PXS.AX PNV.AX PCK.AX PBP.AX PAB.AX OVN.AX OPT.AX OPT OCC.AX NYR.AX NOXOF NOX.AX NC6.AX MXC.AX MX1.AX MVF.AX MEM.AX MDR.AX LBT.AX IPDQF IPD.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX ICR.AX HCT.AX GTG.AX GSS.AX FDMDF DXB.AX CPH.AX CKDXF CGS.AX CALZF BWXXF BWX.AX BPH.AX BITRF BIT.AX ATX.AX ARX.AX ARUXF AMT.AX AMDHF ALC.AX ACR.AX 4DX.AX 1AD.AX

Read more →
Published at

Jan 19, 2023 5:50 PM

by stockhead.com.au

mixed

mixed

Check Up: Japan’s startup OUI wants to halve the world’s blindness with its smartphone device

Japanese startup OUI Inc says it is on a mission to halve the world's blindness with its smartphone-based device.

ZNO.AX ZLD.AX RAP.AX PSQ.AX PIQ.AX PBP.AX PAA.AX MXC.AX IPDQF IPD.AX IDT.AX GLH.AX CGS.AX BXN.AX 1AD.AX SOMNF SOM.AX SHL.AX RSH.AX RGS.AX PGC.AX PCK.AX OVN.AX OSX.AX OSL.AX OIL.AX NYR.AX NXSCF NXS.AX MX1.AX MDC.AX LBT.AX KZIA KZA.AX KMLXF IVX.AX IMMP IMM.AX IHL.AX GSS.AX FDMDF DVL.AX CYP.AX CPH.AX CAN.AX BWXXF BWX.AX BPH.AX BNOEF BNO.AX BITRF BIT.AX AT1.AX ARX.AX AKU.TO AKU ADR.AX 4DX.AX 1ST.AX VTG.AX VLS.AX UBI.AX SCU.AX RNO.AX RHY.AX RHT.AX RAC.AX PYC.AX PXSLY PXS.AX PNV.AX PAB.AX OPT.AX OPT ONE.AX OCC.AX NOXOF NOX.AX NC6.AX MVF.AX MEM.AX MEB.AX MDR.AX MDBIF IUGNF IMU.AX IMRNW IMRN IMC.AX ICR.AX HCT.AX EYE.AX DXB.AX CMP.AX CKDXF CALZF CAJ.AX ATX.AX ARUXF AMT.AX AMDHF ALC.AX ADO.AX ACR.AX

Read more →
Published at

Jan 4, 2023 6:02 PM

by stockhead.com.au

mixed

mixed

Check Up: Moderna posts crazy cancer vaccine results, says melanoma recurrence down by almost half

Moderna’s stock price rose in late December after the company revealed that a vaccine for melanoma showed encouraging results.

TD1.AX RSH.AX PCK.AX MX1.AX KMLXF DVL.AX CAJ.AX BNOEF BNO.AX ARX.AX ADR.AX 1ST.AX ZNO.AX RHY.AX RAC.AX PYC.AX PSQ.AX PGC.AX OVN.AX OSX.AX ONE.AX OCC.AX NOXOF NOX.AX NC6.AX MDC.AX KZA.AX IPDQF IPD.AX IDT.AX GTG.AX CYP.AX CPH.AX CAN.AX BXN.AX BWXXF BWX.AX BPH.AX BITRF BIT.AX ATX.AX ZLD.AX VTG.AX VLS.AX UBI.AX SOMNF SOM.AX SCU.AX RNO.AX RHT.AX RGS.AX PXSLY PXS.AX PNV.AX PBP.AX PAB.AX OSL.AX OPT.AX OPT OIL.AX NYR.AX NXSCF NXS.AX MXC.AX MVF.AX MEM.AX MDR.AX LBT.AX IVX.AX IUGNF IMU.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX ICR.AX HCT.AX GSS.AX GLH.AX FDMDF EYE.AX DXB.AX CMP.AX CKDXF CGS.AX CALZF AT1.AX ARUXF AMT.AX AMDHF ALC.AX ADO.AX ACR.AX 4DX.AX 1AD.AX

Read more →
Published at

Dec 13, 2022 7:02 AM

by globenewswire.com

mixed

mixed

Proactive news headlines including Alligator Energy, Horizon Minerals, AuKing Mining and Hygrovest Ltd

Sydney, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered...

TFPM.TO SORHF SOR.AX PXSLY PXS.AX OZM.AX ORN.JO ORN.AX KWR.AX HRZ.AX HLS.AX CZN.AX CRZNF CPT.AX BOA.AX ALGEF AKN.AX AGE.AX STM.AX RMI.AX KSN.AX IXRRF IXR.AX HMI.AX G1A.AX CRR.AX CML.AX

Read more →
Published at

Nov 30, 2022 8:10 PM

by stockhead.com.au

mixed

mixed

Check Up: The world's most expensive drug costs $3.5 MILLION a shot

The US FDA has just approved the world’s most expensive drug. CSL Behring’s hemophilia B gene therapy costs US$3.5m a dose.

PAB.AX OCC.AX NC6.AX MDR.AX IMM.AX GTG.AX GSS.AX EYE.AX CSLN.MX CSLLY CSL.AX CMXHF BPH.AX SHL.AX RAC.AX PSQ.AX ONE.AX NYR.AX NXSCF NXS.AX MXC.AX KZA.AX FDMDF DXB.AX DVL.AX CYP.AX CPH.AX CGS.AX AT1.AX ARX.AX ARUXF AMDHF ALC.AX ACR.AX 4DX.AX ZNO.AX ZLD.AX VTG.AX VLS.AX UBI.AX TD1.AX SOMNF SOM.AX SCU.AX RSH.AX RNO.AX RHY.AX RHT.AX RGS.AX PYC.AX PXSLY PXS.AX PNV.AX PGC.AX PCK.AX PBP.AX OVN.AX OSX.AX OSL.AX OPT.AX OPT OIL.AX NOXOF NOX.AX MX1.AX MVF.AX MEM.AX MEB.AX MDC.AX MDBIF LBT.AX KMLXF IVX.AX IUGNF IPDQF IPD.AX IMU.AX IMRNW IMRN IMC.AX IHL.AX IDT.AX ICR.AX HCT.AX GLH.AX CMP.AX CKDXF CAN.AX CALZF CAJ.AX BXN.AX BWXXF BWX.AX BNOEF BNO.AX BITRF BIT.AX ATX.AX AMT.AX ADR.AX ADO.AX 1ST.AX 1AD.AX

Read more →
Published at

Nov 23, 2022 7:50 PM

by stockhead.com.au

mixed

mixed

How out of favour Biotech has a PR problem and could learn from Dr Karl

ASX health stocks have fallen out of favour in 2022 with a a rotation out of growth into value sectors but could it also do with better PR?

VTG.AX NEU.AX MXC.AX KZA.AX CSL.AX COH.AX BWXXF BWX.AX AT1.AX ADR.AX ADO.AX ZNO.AX ZLD.AX UBI.AX TD1.AX SHL.AX RSH.AX RHT.AX RAC.AX PNV.AX PBP.AX OVN.AX OSX.AX OSL.AX OCC.AX NOXOF NOX.AX MVF.AX MEM.AX MEB.AX MDC.AX MDBIF LBT.AX KMLXF IUGNF IMU.AX ICS.AX ICR.AX EYE.AX CPH.AX CMP.AX CALZF BXN.AX AMDHF 1ST.AX VLS.AX SOMNF SOM.AX SCU.AX RNO.AX RHY.AX RGS.AX PYC.AX PXSLY PXS.AX PSQ.AX PGC.AX PCK.AX PAB.AX OPT.AX OPT ONE.AX OIL.AX NYR.AX NXSCF NXS.AX MX1.AX MDR.AX IVX.AX IPDQF IPD.AX IMRNW IMRN IMM.AX IMC.AX IHL.AX IDT.AX HCT.AX GTG.AX GSS.AX GLH.AX FDMDF DXB.AX DVL.AX CYP.AX CKDXF CGS.AX CAN.AX CAJ.AX BPH.AX BNOEF BNO.AX BITRF BIT.AX ATX.AX ARX.AX ARUXF AMT.AX ALC.AX ACR.AX 4DX.AX 1AD.AX

Read more →
Published at

Nov 2, 2022 8:30 PM

by stockhead.com.au

mixed

mixed

Check Up: These 4 ASX healthcare stocks come with Strong Buy recommendations

Four ASX healthcare stocks have been rated as a ‘Strong Buy' by Morningstar’s consensus of brokers, making them hot tips.

ZNO.AX RHT.AX LBT.AX KZA.AX IUGNF IMU.AX ICR.AX EPN.AX ARX.AX ARUXF AMT.AX ALC.AX ACR.AX 1ST.AX ZLD.AX RAC.AX PNV.AX PBP.AX ONE.AX OIL.AX NXSCF NXS.AX MDR.AX IPDQF IPD.AX IMRNW IMRN IMC.AX GTG.AX GSS.AX GLH.AX FDMDF EYE.AX CYP.AX CALZF BNOEF BNO.AX 4DX.AX VTG.AX VLS.AX UBI.AX TD1.AX SOMNF SOM.AX SCU.AX RSH.AX RNO.AX RHY.AX RGS.AX PYC.AX PXSLY PXS.AX PSQ.AX PGC.AX PCK.AX PAB.AX OVN.AX OSX.AX OSL.AX OPT.AX OPT OCC.AX NYR.AX NOXOF NOX.AX NC6.AX MXC.AX MX1.AX MVF.AX MEM.AX MEB.AX MDC.AX MDBIF KMLXF IVX.AX IMM.AX IHL.AX IDT.AX HCT.AX DXB.AX DVL.AX CPH.AX CMP.AX CKDXF CGS.AX CAN.AX CAJ.AX BXN.AX BWXXF BWX.AX BPH.AX BITRF BIT.AX ATX.AX AT1.AX AMDHF ADR.AX ADO.AX 1AD.AX

Read more →
Published at

Oct 20, 2022 9:00 PM

by stockhead.com.au

mixed

mixed

Check Up: Only two healthcare IPOs from 2021 are gaining ground, could the rest be buying opportunities?

There were 191 ASX IPOs in calendar year 2021, and 15 of them were biotech stocks.But in 2022 there were only 3 biotech listings.

PXSLY PXS.AX PAB.AX OSL.AX MEM.AX ILA.AX GLH.AX CAJ.AX BPH.AX AMDHF AGN.AX ZLD.AX UBI.AX TD1.AX SCU.AX RSH.AX RNO.AX RHY.AX RGS.AX PYC.AX PGC.AX PBP.AX OSX.AX OPT.AX OPT OIL.AX OCC.AX NXSCF NXS.AX NOXOF NOX.AX NC6.AX MXC.AX MEB.AX MDR.AX MDC.AX MDBIF KMLXF IPDQF IPD.AX IMRNW IMRN IMC.AX IHL.AX HXL.AX GTG.AX EYE.AX DVL.AX CPH.AX CKDXF BWXXF BWX.AX BITRF BIT.AX AT1.AX ARUXF ACR.AX 1ST.AX ZNO.AX VTG.AX VLS.AX SOMNF SOM.AX RHT.AX RAC.AX PSQ.AX PNV.AX PCK.AX OVN.AX ONE.AX NYR.AX MX1.AX MVF.AX LBT.AX KZA.AX IVX.AX IUGNF IMU.AX IMM.AX IDT.AX ICR.AX HCT.AX GSS.AX FDMDF DXB.AX CYP.AX CMP.AX CGS.AX CAN.AX CALZF BXN.AX BNOEF BNO.AX ATX.AX ARX.AX AMT.AX ALC.AX ADR.AX ADO.AX ACW.AX 4DX.AX 1AD.AX

Read more →